5.25
-0.085(-1.59%)
Currency In USD
| Previous Close | 5.33 |
| Open | 5.29 |
| Day High | 5.31 |
| Day Low | 5.19 |
| 52-Week High | 7.54 |
| 52-Week Low | 3.93 |
| Volume | 736,575 |
| Average Volume | 937,579.6 |
| Market Cap | 268.95M |
| PE | 8.2 |
| EPS | 0.64 |
| Moving Average 50 Days | 6.46 |
| Moving Average 200 Days | 5.83 |
| Change | -0.09 |
If you invested $1000 in Abeona Therapeutics Inc. (ABEO) 10 years ago, it would be worth $51.8 as of September 30, 2025 at a share price of $5.245. Whereas If you bought $1000 worth of Abeona Therapeutics Inc. (ABEO) shares 5 years ago, it would be worth $205.69 as of September 30, 2025 at a share price of $5.245.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
GlobeNewswire Inc.
Aug 29, 2025 11:30 AM GMT
CLEVELAND, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2025: Cantor Global Healthcare Conference 2025:
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area
GlobeNewswire Inc.
Jul 15, 2025 11:30 AM GMT
- Lucile Packard Children’s Hospital Stanford is ready to accept patients for ZEVASKYN treatment - - Abeona Therapeutics® and Stanford Medicine conducted research collaboration for more than a decade, culminating in U.S. Food and Drug Administration
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million
GlobeNewswire Inc.
Jul 02, 2025 11:30 AM GMT
Cash resources totaled approximately $225 million as of June 30, 2025CLEVELAND, July 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher